263 related articles for article (PubMed ID: 26453883)
1. Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization.
Achour O; Poupard N; Bridiau N; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2016 Jan; 135():316-23. PubMed ID: 26453883
[TBL] [Abstract][Full Text] [Related]
2. Production of heparin and Ī»-carrageenan anti-heparanase derivatives using a combination of physicochemical depolymerization and glycol splitting.
Poupard N; Groult H; Bodin J; Bridiau N; Bordenave-Juchereau S; Sannier F; Piot JM; Fruitier-Arnaudin I; Maugard T
Carbohydr Polym; 2017 Jun; 166():156-165. PubMed ID: 28385219
[TBL] [Abstract][Full Text] [Related]
3. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase.
Yu Y; Fu L; He P; Xia K; Varghese S; Dordick J; Wang H; Zhang F; Linhardt RJ
Carbohydr Polym; 2022 Nov; 295():119825. PubMed ID: 35988993
[TBL] [Abstract][Full Text] [Related]
5. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
7. Non-Anticoagulant Heparins as Heparanase Inhibitors.
Cassinelli G; Torri G; Naggi A
Adv Exp Med Biol; 2020; 1221():493-522. PubMed ID: 32274724
[TBL] [Abstract][Full Text] [Related]
8. Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.
Wu J; Zhang C; Mei X; Li Y; Xing XH
Carbohydr Polym; 2014 Jan; 101():484-92. PubMed ID: 24299802
[TBL] [Abstract][Full Text] [Related]
9. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
[TBL] [Abstract][Full Text] [Related]
10. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.
Alekseeva A; Mazzini G; Giannini G; Naggi A
Carbohydr Polym; 2017 Jan; 156():470-480. PubMed ID: 27842848
[TBL] [Abstract][Full Text] [Related]
11. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.
Elli S; Guerrini M
Adv Exp Med Biol; 2020; 1221():169-188. PubMed ID: 32274710
[TBL] [Abstract][Full Text] [Related]
12. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
[TBL] [Abstract][Full Text] [Related]
14. Development of low molecular weight heparin by H
Shen X; Liu Z; Li J; Wu D; Zhu M; Yan L; Mao G; Ye X; Linhardt RJ; Chen S
Int J Biol Macromol; 2019 Jul; 133():101-109. PubMed ID: 30954594
[TBL] [Abstract][Full Text] [Related]
15. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ
Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143
[TBL] [Abstract][Full Text] [Related]
16. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
17. Heparanase in Cancer MetastasisĀ - Heparin as a Potential Inhibitor of Cell Adhesion Molecules.
Bendas G; Borsig L
Adv Exp Med Biol; 2020; 1221():309-329. PubMed ID: 32274715
[TBL] [Abstract][Full Text] [Related]
18. Heparanase as an Additional Tool for Detecting Structural Peculiarities of Heparin Oligosaccharides.
Alekseeva A; Urso E; Mazzini G; Naggi A
Molecules; 2019 Dec; 24(23):. PubMed ID: 31810297
[TBL] [Abstract][Full Text] [Related]
19. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
Hostettler N; Naggi A; Torri G; Ishai-Michaeli R; Casu B; Vlodavsky I; Borsig L
FASEB J; 2007 Nov; 21(13):3562-72. PubMed ID: 17557930
[TBL] [Abstract][Full Text] [Related]
20. Non-anticoagulant heparins and inhibition of cancer.
Casu B; Vlodavsky I; Sanderson RD
Pathophysiol Haemost Thromb; 2008; 36(3-4):195-203. PubMed ID: 19176992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
